These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1152 related articles for article (PubMed ID: 23268517)
1. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Heathcote EJ; Manns MP; Kuske L; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL JAMA; 2012 Dec; 308(24):2584-93. PubMed ID: 23268517 [TBL] [Abstract][Full Text] [Related]
2. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234 [TBL] [Abstract][Full Text] [Related]
3. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis. Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J J Gastroenterol Hepatol; 2017 Mar; 32(3):687-694. PubMed ID: 27577675 [TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response. Cordero-Ruiz P; Carmona-Soria I; Rodríguez-Téllez M; Caunedo-Alvarez A; Quezada-Pacheco RH; Flores-Cucho A; Romero-Gómez M; Vilches-Arenas Á Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):792-799. PubMed ID: 28445251 [TBL] [Abstract][Full Text] [Related]
5. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection. Casado JL; Quereda C; Moreno A; Pérez-Elías MJ; Martí-Belda P; Moreno S J Viral Hepat; 2013 Dec; 20(12):829-37. PubMed ID: 24304452 [TBL] [Abstract][Full Text] [Related]
6. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714 [TBL] [Abstract][Full Text] [Related]
7. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Innes HA; McDonald SA; Dillon JF; Allen S; Hayes PC; Goldberg D; Mills PR; Barclay ST; Wilks D; Valerio H; Fox R; Bhattacharyya D; Kennedy N; Morris J; Fraser A; Stanley AJ; Bramley P; Hutchinson SJ Hepatology; 2015 Aug; 62(2):355-64. PubMed ID: 25716707 [TBL] [Abstract][Full Text] [Related]
8. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J Liver Int; 2016 Jun; 36(6):817-26. PubMed ID: 26787002 [TBL] [Abstract][Full Text] [Related]
9. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Berenguer J; Alvarez-Pellicer J; Martín PM; López-Aldeguer J; Von-Wichmann MA; Quereda C; Mallolas J; Sanz J; Tural C; Bellón JM; González-García J; Hepatology; 2009 Aug; 50(2):407-13. PubMed ID: 19575364 [TBL] [Abstract][Full Text] [Related]
10. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553 [TBL] [Abstract][Full Text] [Related]
11. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment. Kozbial K; Moser S; Al-Zoairy R; Schwarzer R; Datz C; Stauber R; Laferl H; Strasser M; Beinhardt S; Stättermayer AF; Gschwantler M; Zoller H; Maieron A; Graziadei I; Trauner M; Steindl-Munda P; Hofer H; Ferenci P Liver Int; 2018 Jun; 38(6):1028-1035. PubMed ID: 29136329 [TBL] [Abstract][Full Text] [Related]
12. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL J Viral Hepat; 2014 Aug; 21(8):568-77. PubMed ID: 24118177 [TBL] [Abstract][Full Text] [Related]
13. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. van der Meer AJ; Maan R; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL J Gastroenterol Hepatol; 2016 Jun; 31(6):1168-76. PubMed ID: 26647353 [TBL] [Abstract][Full Text] [Related]
14. Is there sufficient evidence to recommend antiviral therapy in hepatitis C? van der Meer AJ; Wedemeyer H; Feld JJ; Hansen BE; Manns MP; Zeuzem S; Janssen HL J Hepatol; 2014 Jan; 60(1):191-6. PubMed ID: 23973931 [TBL] [Abstract][Full Text] [Related]
15. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES. Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS; Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403 [TBL] [Abstract][Full Text] [Related]
16. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. Maan R; Zaim R; van der Meer AJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Manns MP; Zeuzem S; Hansen BE; Janssen H; Veldt BJ; de Knegt RJ; Uyl-de Groot CA J Gastroenterol Hepatol; 2016 Nov; 31(11):1851-1859. PubMed ID: 26990109 [TBL] [Abstract][Full Text] [Related]
17. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study. Nagaoki Y; Aikata H; Nakano N; Shinohara F; Nakamura Y; Hatooka M; Morio K; Kan H; Fujino H; Kobayashi T; Fukuhara T; Masaki K; Ono A; Nakahara T; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Imamura M; Takahashi S; Kawakami Y; Ochi H; Chayama K; J Gastroenterol Hepatol; 2016 May; 31(5):1009-15. PubMed ID: 26584407 [TBL] [Abstract][Full Text] [Related]
18. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Bruno S; Zuin M; Crosignani A; Rossi S; Zadra F; Roffi L; Borzio M; Redaelli A; Chiesa A; Silini EM; Almasio PL; Maisonneuve P Am J Gastroenterol; 2009 May; 104(5):1147-58. PubMed ID: 19352340 [TBL] [Abstract][Full Text] [Related]
19. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370 [TBL] [Abstract][Full Text] [Related]
20. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Morgan TR; Ghany MG; Kim HY; Snow KK; Shiffman ML; De Santo JL; Lee WM; Di Bisceglie AM; Bonkovsky HL; Dienstag JL; Morishima C; Lindsay KL; Lok AS; Hepatology; 2010 Sep; 52(3):833-44. PubMed ID: 20564351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]